Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.

Neoplasia (New York, N.Y.) - 1 Jun 2024

Xu Qianqian, Wang Jiaqi, Mao Yuting, Xuan Ziyang, Yang Ke, Tang Xi, Zhu Xin

Abstract excerpt

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, and its incidence has increased rapidly in recent years. The BRAF inhibitor vemurafenib is effective against BRAFV600E-positive PTC; however, acquired resistance to single agent therapy frequently leads to tumor recurrence and metastasis, underscoring the need to develop tailored treatment strategies. We previously showed that the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38593698
DOI: 10.1016/j.neo.2024.100996
PMCID: PMC11007432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.PMID 38593698Read ↗

Metabolomic analysis of human papillary thyroid carcinoma using UPLC-Q- TOFMSSemantic proximity Read ↗

Integrative Multi-omics Analysis Reveals Different Metabolic Phenotypes Based on Molecular Characteristics in Thyroid Cancer.Semantic proximity Read ↗

The Relevance between Iodine Nutritional Status and BRAFV600E Mutation on Papillary Thyroid CancerSemantic proximity Read ↗

Multi-Omics Analysis of Fatty Acid Metabolism in Thyroid CarcinomaSemantic proximity Read ↗

BRAF Mutation Affects Intratumor Heterogeneity in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

BRAFV600E/p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer.Semantic proximity Read ↗

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.Semantic proximity Read ↗

Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.Semantic proximity Read ↗

A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).Semantic proximity Read ↗

Synergistic Effect of Metformin and Vemurufenib (PLX4032) as a Molecular Targeted Therapy in Anaplastic Thyroid Cancer – An In Vitro StudySemantic proximity Read ↗

Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.